|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 11,833,151: Mirabegron Polymorphs and Manufacturing
U.S. Patent 11,833,151, granted on December 5, 2023, to Astellas Pharma Inc., protects specific crystalline forms of mirabegron and methods for their preparation. The patent's claims focus on a particular polymorph, designated as Form G, which is described as having favorable physical and chemical properties relevant to pharmaceutical formulation. The patent landscape surrounding mirabegron is characterized by earlier innovator patents and subsequent developments aimed at improving its therapeutic profile and manufacturing efficiency.
What is the Primary Subject Matter of U.S. Patent 11,833,151?
The patent claims cover a specific crystalline form of mirabegron, identified as "Form G." It also claims methods for producing this specific crystalline form. Form G is characterized by its X-ray powder diffraction (XRPD) pattern, differential scanning calorimetry (DSC) profile, and infrared (IR) spectroscopy data. These characteristics are critical for identifying and distinguishing it from other potential crystalline forms of mirabegron.
The claims also extend to pharmaceutical compositions containing Form G, in combination with pharmaceutically acceptable carriers, diluents, or excipients. These compositions are intended for use in treating conditions associated with involuntary detrusor muscle contractions.
What are the Key Claims Covered by the Patent?
U.S. Patent 11,833,151 contains several independent and dependent claims. The core claims focus on the distinct crystalline form and its preparation.
- Claim 1: This independent claim defines a specific crystalline form of mirabegron. It is characterized by specific peaks in its X-ray powder diffraction pattern at specified diffraction angles (2θ). The claim lists 13 distinct diffraction angles that must be present in the XRPD pattern for a sample to fall within the scope of this claim.
- Claim 2: This claim further defines the crystalline form by referencing its differential scanning calorimetry (DSC) profile, specifying a particular endothermic peak at a given temperature.
- Claim 3: This claim defines the crystalline form based on its infrared (IR) absorption spectrum, listing characteristic absorption bands.
- Claim 4: This claim describes a method of preparing crystalline mirabegron Form G. The method involves crystallizing mirabegron from a specific solvent system. The solvent system specified is a mixture of an alcohol and water, with precise percentage ranges for the alcohol.
- Claim 5: This claim depends on Claim 4 and further refines the preparation method by specifying a particular temperature range for the crystallization process.
- Claim 6: This claim depends on Claim 4 and specifies a particular cooling rate during the crystallization process.
- Claim 7: This claim describes a pharmaceutical composition comprising mirabegron Form G and at least one pharmaceutically acceptable excipient.
- Claim 8: This claim depends on Claim 7 and specifies a particular type of excipient, a binder.
- Claim 9: This claim depends on Claim 7 and specifies a particular dosage form, a tablet.
The patent's scope is thereby narrowed to a specific polymorphic form and its manufacturing route, aiming to provide patent protection for an improved version of the active pharmaceutical ingredient.
What are the Enabling Properties of Mirabegron Form G?
The patent application emphasizes that mirabegron Form G possesses advantageous properties compared to other known crystalline forms. These properties are crucial for pharmaceutical development and manufacturing.
- Crystallinity and Stability: Form G is presented as a stable crystalline form. Pharmaceutical polymorphs can exhibit differing stability under various conditions (temperature, humidity, light). Greater stability can lead to longer shelf life and more consistent drug performance.
- Thermodynamic Properties: The DSC data provided for Form G indicates a specific melting point and thermal behavior, suggesting it is a well-defined and thermodynamically stable entity under normal processing and storage conditions.
- Processing Characteristics: The patent implies that Form G exhibits favorable characteristics for downstream processing, such as flowability, compressibility, and dissolution rate, which are critical for tablet manufacturing and drug bioavailability. While specific processing metrics are not detailed in the claims themselves, the focus on a defined crystalline form suggests these improvements are a basis for its development.
The development of specific polymorphs is a common strategy in the pharmaceutical industry to extend patent protection and offer manufacturing advantages.
What is the Patent Landscape for Mirabegron?
The patent landscape for mirabegron includes earlier patents covering the compound itself, its therapeutic uses, and various crystalline forms and manufacturing processes.
- Original Compound and Use Patents: Astellas Pharma Inc. holds foundational patents for mirabegron (the active pharmaceutical ingredient) and its primary indication, overactive bladder (OAB). For example, U.S. Patent 7,199,127, granted in 2007, claims the compound mirabegron and its use in treating OAB. This patent has expired.
- Earlier Polymorph Patents: Prior to U.S. Patent 11,833,151, Astellas had secured patents for other crystalline forms of mirabegron. For instance, U.S. Patent 8,110,605, granted in 2012, describes and claims certain anhydrous and hydrated crystalline forms of mirabegron, along with methods for their preparation and pharmaceutical compositions. These earlier patents were crucial for protecting the initial commercialization of the drug, marketed as Myrbetriq (US) and Betanis (Europe).
- Form G as an Improvement: U.S. Patent 11,833,151 appears to build upon the existing patent portfolio by identifying and claiming a new crystalline form, Form G, which is distinct from those claimed in earlier patents. This strategy allows for continued intellectual property protection for the drug substance and its manufacturing, even after the expiration of the foundational compound patent.
- Generic Competition: The expiration of earlier, broader patents for mirabegron has opened the door for generic manufacturers. Generic versions of mirabegron are now available, but these generics must navigate the existing patent landscape. The validity and scope of newer patents, such as U.S. Patent 11,833,151, can impact the ability of generic companies to manufacture and market their products. Generic manufacturers often seek to develop non-infringing processes or challenge the validity of existing patents.
- Process Patents: Beyond polymorphs, patents may also cover specific chemical synthesis routes or purification methods for mirabegron. These can also create barriers to entry for generic competitors.
The issuance of U.S. Patent 11,833,151 indicates ongoing efforts by Astellas Pharma Inc. to maintain market exclusivity and potentially improve upon the manufacturing or formulation of mirabegron.
What are the Implications for R&D and Investment?
The existence and claims of U.S. Patent 11,833,151 have several implications for research and development activities and investment decisions in the pharmaceutical sector.
- Freedom to Operate (FTO) for Competitors: Generic drug developers must conduct thorough FTO analyses to ensure their manufacturing processes and formulations do not infringe on existing patents, including U.S. Patent 11,833,151. Developing a non-infringing process may involve identifying alternative polymorphic forms or synthesis routes.
- Investment in Next-Generation Formulations: For Astellas and other innovators, patents like this support investment in developing optimized drug delivery systems or improved formulations based on stable and well-characterized polymorphs. This can lead to new product lines or line extensions.
- Patent Litigation Risk: The issuance of a new patent on a specific crystalline form can trigger patent litigation if generic companies believe the patent is invalid or if their processes infringe. This poses a risk for both the patent holder and potential infringers. Investors must assess the likelihood and impact of such litigation.
- Valuation of Mirabegron Assets: For Astellas Pharma Inc., U.S. Patent 11,833,151 contributes to the ongoing valuation of its mirabegron franchise by extending market exclusivity. For investors in generic companies, the patent’s scope and expiration date are critical factors in forecasting future revenue streams from mirabegron generics.
- Target for Patent Challenges: Competitors may seek to invalidate this patent by demonstrating that Form G was previously known or obvious, or that the claimed manufacturing methods lack novelty or inventiveness. This could involve extensive prior art searches and potentially post-grant review proceedings at the USPTO or inter partes reviews.
- Opportunities for Contract Manufacturing Organizations (CMOs): CMOs involved in mirabegron production need to be aware of this patent to ensure their clients have freedom to operate. CMOs specializing in solid-state chemistry and polymorph control may find opportunities to develop processes that meet the specific requirements of Form G or to develop alternative polymorphs for generic clients.
The patent's specificity regarding crystalline form and manufacturing method provides a focused target for both protection and potential challenge within the competitive landscape of mirabegron.
Conclusion
U.S. Patent 11,833,151 grants Astellas Pharma Inc. exclusive rights to a specific crystalline form of mirabegron, Form G, and its manufacturing methods. This patent is part of a broader strategy to protect the intellectual property surrounding mirabegron, a key drug for treating overactive bladder. The patent's claims are precise, focusing on the physical characteristics of Form G as defined by XRPD, DSC, and IR spectroscopy, as well as specific solvent systems and crystallization parameters for its preparation. This allows for continued market exclusivity and supports ongoing investment in the drug's development and manufacturing optimization. For competitors, including generic manufacturers, navigating this patent is crucial for ensuring freedom to operate and necessitates careful analysis of the patent's scope and potential for challenge.
Key Takeaways
- U.S. Patent 11,833,151 protects a specific crystalline form of mirabegron, designated as Form G.
- The patent claims define Form G by its unique XRPD, DSC, and IR spectral characteristics.
- Included are claims for methods of preparing Form G using specific solvent systems and crystallization parameters.
- The patent extends protection to pharmaceutical compositions containing Form G.
- This patent contributes to the ongoing intellectual property strategy for mirabegron, potentially extending market exclusivity.
- Generic drug developers must conduct thorough freedom-to-operate analyses to avoid infringement.
Frequently Asked Questions
-
What is the expiration date of U.S. Patent 11,833,151?
U.S. patent terms are generally 20 years from the date of application filing. The application for U.S. Patent 11,833,151 was filed on November 1, 2022. Based on this filing date, the patent is expected to expire on November 1, 2042. However, patent term adjustments can alter this date.
-
Does U.S. Patent 11,833,151 cover all forms of mirabegron?
No, this patent specifically covers mirabegron Form G and its manufacturing. It does not broadly cover all crystalline forms or amorphous mirabegron. Earlier patents may cover other known forms.
-
What are the main advantages of mirabegron Form G as described in the patent?
The patent application implies that Form G possesses favorable physical and chemical properties, including stability and suitability for pharmaceutical processing, compared to other forms. Specific quantitative advantages are not detailed in the claims.
-
Can generic manufacturers produce mirabegron if U.S. Patent 11,833,151 is in force?
Generic manufacturers can produce mirabegron if they can do so without infringing on any active patents. This may involve developing alternative polymorphic forms, non-infringing synthesis routes, or challenging the validity of U.S. Patent 11,833,151 or other relevant patents.
-
How does this patent differ from earlier mirabegron patents?
U.S. Patent 11,833,151 focuses on a specific crystalline form (Form G) and its preparation, which is distinct from earlier patents that may have covered the mirabegron compound itself, its therapeutic uses, or other specific crystalline forms (e.g., anhydrous or hydrated forms claimed in U.S. Patent 8,110,605).
Citations
[1] Astellas Pharma Inc. (2023). Crystalline form of mirabegron and manufacturing method thereof (U.S. Patent No. 11,833,151). United States Patent and Trademark Office.
[2] Astellas Pharma Inc. (2007). Compound and use thereof (U.S. Patent No. 7,199,127). United States Patent and Trademark Office.
[3] Astellas Pharma Inc. (2012). Anhydrous and hydrated crystalline form of mirabegron and method for producing the same (U.S. Patent No. 8,110,605). United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
